July 25 - 27, 2017    Boston MA , USA
The growing disease burden and emergence of innovative new therapeutics means that the multi-billion dollar ophthalmic drug market is poised for near double digit compound growth over the next 5 years. There is enormous untapped potential for companies focusing on developing novel approaches to tackle age related macular degeneration, diabetic macular edema, glaucoma and other degenerative ocular conditions. Focussing specifically on the challenges drug developers face in the development and delivery of clinically effective ocular drugs, the 2nd Annual Ophthalmic Drug Development Summit is your opportunity to fast-track your development efforts in this space. Rather than covering early stage research or pipeline overviews, this meeting will unite leaders from Novartis, Genentech, Santen, Astellas and Spark Therapeutics to deliver granular, in-depth insights that will help you accelerate the progress of your ocular drug pipeline.


Location: Hyatt Regency Boston
Discover why Hyatt Regency Boston has been the recipient of numerous accolades including the Successful Meetings Pinnacle Award. Minutes from Logan Airport, the Hynes Convention Center and a multitude..
Contact One Avenue Lafayette Boston , USA
+1 617 912 1234


Hanson Wade
52 Grosvenor Gardens, London SW1W 0AU
+44 (0)20 3141 8700

Related events